Pamidronate Side Effects
It is possible that some side effects of pamidronate may not have been reported. These can be reported to the FDA here. Always consult a healthcare professional for medical advice.
For the Consumer
Applies to pamidronate: intravenous powder for solution, intravenous solution
As well as its needed effects, pamidronate may cause unwanted side effects that require medical attention.
If any of the following side effects occur while taking pamidronate, check with your doctor or nurse immediately:More common
- Abdominal or stomach cramps
- black, tarry stools
- bloody in the urine or stools
- blurred vision
- chest pain
- convulsions (seizures)
- decrease in the amount of urine
- fast or irregular heartbeat
- increased thirst
- loss of appetite
- muscle pain, cramps, spasms, or twitching
- nausea or vomiting
- noisy, rattling breathing
- numbness or tingling in the hands, feet, or lips
- pinpoint red spots on the skin
- pounding in the ears
- shortness of breath
- slow or fast heartbeat
- swelling of the fingers, hands, feet, or lower legs
- troubled breathing at rest
- unusual bleeding or bruising
- unusual tiredness or weakness
- vomiting of blood or material that looks like coffee grounds
- weight gain
- dilated neck veins
- extreme fatigue
- irregular breathing
- lower back or side pain
- painful or difficult urination
- pale skin
- ulcers, sores, or white spots in the mouth
- Decreased vision
- difficulty with swallowing
- eye pain or tenderness
- eye redness
- large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
- sensitivity of the eye to light
- skin rash
- tearing of the eye
- tightness in the chest
- Bone, joint, or muscle pain, severe and occasionally incapacitating
- faintness, or lightheadedness when getting up suddenly from a lying or sitting position
Some pamidronate side effects may not need any medical attention. As your body gets used to the medicine these side effects may disappear. Your health care professional may be able to help you prevent or reduce these side effects, but do check with them if any of the following side effects continue, or if you are concerned about them:More common
- Acid or sour stomach
- bladder pain
- bloody or cloudy urine
- body aches or pain
- bone pain
- cracks in the skin at the corners of mouth
- difficult, burning, or painful urination
- difficult or labored breathing
- difficulty moving
- ear congestion
- frequent urge to urinate
- joint pain
- lack or loss of strength
- lower back or side pain
- muscle aching, cramping, pains, or stiffness
- nasal congestion
- pain and swelling at the injection site
- sensitivity to heat
- soreness or redness around the fingernails and toenails
- stomach discomfort, upset, or pain
- swollen joints
- trouble sleeping
- weight loss
- Ammonia-like breath odor
- feeling, seeing, or hearing things that are not there
- feeling that others are watching you or controlling your behavior
- feeling that others can hear your thoughts
- feeling unusually cold
- swelling or inflammation of the mouth
- unusual behavior
For Healthcare Professionals
Applies to pamidronate: intravenous powder for injection, intravenous solution
Pamidronate has been generally well tolerated and many adverse effects that occurred during treatment may have been related to the underlying disease state. Adverse effects have been most often associated with larger (90 mg) doses of pamidronate. The most common adverse effect has been fever, occurring in up to 41% of patients. The fever was generally mild and transient. Onset was typically within the first 48 hours after infusion and resolution was within another 48 hours.
In patients with osteolytic bone involvement associated with breast cancer and multiple myeloma, the most commonly reported (>15%) adverse effects occurred with similar frequency in pamidronate and placebo treatment groups.
Five pamidronate associated serious and unexpected adverse events occurred in multiple myeloma patients during clinical trials. Symptoms included worsening renal function or multiple myeloma associated amyloidosis (3), adult respiratory distress syndrome (1), and an allergic reaction after the sixth infusion (1).
Four breast cancer patients discontinued pamidronate because of serious adverse events including interstitial pneumonitis, malaise, dyspnea, symptomatic hypocalcemia, and severe bone pain.
Local side effects associated with intravenous infusion have been reported in up to 18% of patients and included phlebitis as well as redness, swelling, and pain at the injection site.
Metabolic side effects have included hypophosphatemia (18%), hypokalemia (18%), hypocalcemia (12%), and hypomagnesemia (12%). While usually asymptomatic, rare cases of symptomatic hypocalcemia have been reported.
Presentation of hypocalcemia may be delayed. In one case report, the patient presented with fingertip paresthesias and a serum calcium of 6.8 mEq/L (7.8 mEq/mL, corrected) 13 days after a single infusion of pamidronate.
Leukopenia was generally mild and transient. In one study, granulocytopenia occurred in 4.2% of patients but completely resolved after discontinuation of pamidronate therapy. Patients with anemia, leukopenia, or thrombocytopenia prior to initiation of pamidronate should be carefully monitored during the first 2 weeks of therapy.
Hematologic side effects have included anemia, mild leukopenia, and granulocytopenia. Chronic idiopathic thrombocytopenic purpura has also been cited in a case report.
Renal side effects have included postmarketing reports of focal segmental glomerulosclerosis including the collapsing variant and nephrotic syndrome. Monitoring of renal function during and following pamidronate therapy is recommended.
Uveitis generally occurs within 24 to 48 hours after administration of pamidronate. The uveitis may be bilateral, and reversible, partial 3rd and 4th nerve palsies have been reported with the uveitis. Recurrences have occurred with rechallenge of the drug. Therapy with pamidronate should be discontinued if uveitis occurs. Although severe cases have been reported, most symptoms have resolved on discontinuation of pamidronate with minimal or no intervention.
A nonspecific conjunctivitis has been reported with pamidronate use. The conjunctivitis may consist of any or all of the following symptoms: conjunctival hyperemia, irritation, epiphora, discharge, and blurred vision. These symptoms may appear within the first 6 to 48 hours after administration of the drug and generally resolve within a few days after drug discontinuation.
Ocular side effects have included abnormal vision as well as uveitis, iritis, episcleritis, scleritis, and nonspecific transitory conjunctivitis. Post marketing reports have included orbital inflammation.
Musculoskeletal side effects have included worsening of bone pain, arthralgias, and myalgias. In addition, cases of osteomalacia and mineralization defects have been reported. Post marketing reports have included cases of osteonecrosis, primarily of the jaws.
Nervous system side effects have included headache in 15% of patients with Paget's disease receiving pamidronate. Insomnia, somnolence, and psychoses have also been reported. Seizures have been reported although causality has not been established. Postmarketing reports have included confusion and visual hallucinations, sometimes in the presence of electrolyte imbalance.
In one study, 4.7% of patients taking oral pamidronate required interruption of therapy due to gastrointestinal side effects.
Gastrointestinal side effects have been more frequently reported with oral pamidronate (not available in the United States) than with the IV formulation and have included abdominal pain, anorexia, constipation, diarrhea, stomatitis, gastrointestinal hemorrhage, nausea, and vomiting.
Other side effects have included rigors (3% to 8%) and general malaise (9% to 12%).
Cardiovascular side effects such as fluid overload and hypertension have occurred in at least 15% of patients treated with pamidronate during clinical trials. Rare cases of atrial fibrillation, atrial flutter, tachycardia, syncope, and cardiac failure have been reported.
Genitourinary side effects have included urinary tract infections (15%) and moniliasis (6%).
Respiratory side effects including dyspnea, rales, rhinitis, and upper respiratory infections have been uncommon and occurred more frequently with larger doses of pamidronate.
Endocrine side effects have been uncommon. Hypothyroidism has been reported in patients receiving 90 mg of pamidronate .
Other side effects have included postmarketing reports of reactivation of Herpes simplex and Herpes zoster and influenza-like symptoms.
Dermatologic side effects have included postmarketing reports of rash and pruritus.
More about pamidronate
- Other brands: Aredia
Related treatment guides
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.